TITLE

Human papillomavirus prevalence in the U.S

AUTHOR(S)
Weintrub, Peggy Sue
PUB. DATE
July 2007
SOURCE
Archives of Disease in Childhood;Jul2007, Vol. 92 Issue 7, p650
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a summary of a study on the prevalence of human papillomavirus (HPV) in the U.S. as well as its commentary. Results of the study shows that for all age groups combined, the prevalence of HPV was 26.8 percent. The author points out that the low rate of high-risk HPV types does not change her enthusiasm for the new vaccine, which shows great promise in preventing many cases of cervical cancer.
ACCESSION #
25765857

 

Related Articles

  • HPV and Cervical Cancer. Leaver, Dennis; Labonte, Geri // Radiation Therapist;Spring2010, Vol. 19 Issue 1, p27 

    Human papillomaviruses (HPVs) are estimated to cause a half million cases of cervical cancer worldwide each year. This article reviews the connection between HPVs and cervical cancer, discusses the HPV vaccine and provides an overview of cervical cancer symptoms, staging and treatment. Case...

  • What If Preventing Cancer Is as Easy as Being Vaccinated? Biedrzycki, Barbara A. // ONS News;Aug2006, Vol. 21 Issue 8, p9 

    The article reports on the development of a human papillomavirus (HPV) vaccine intended for the prevention of cervical cancer among men and women worldwide. HPV has been sought to be the most common sexually transmitted disease with 20 million men and women have been infected. With the approval...

  • Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program. Demarteau, Nadia; Breuer, Thomas; Standaert, Baudouin // PharmacoEconomics;2012, Vol. 30 Issue 4, p337 

    Background: Screening and vaccination against human papillomavirus (HPV) can protect against cervical cancer. Neither alone can provide 100% protection. Consequently it raises the important question about the most efficient combination of screening at specified time intervals and vaccination to...

  • Gardasil — the perfect guard? Goymer, Patrick // Nature Reviews Cancer;Nov2005, Vol. 5 Issue 11, p840 

    The article reports that Merck & Co. have announced the effectiveness of their vaccine against cervical cancer Gardasil in a phase III clinical trial. Gardasil is directed against human papilloma virus (HPV) 16 and HPV18. Still, there are other cancer-causing strains of HPV which the vaccine...

  • Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Stanley, M. // British Journal of Cancer;5/7/2007, Vol. 96 Issue 9, p1320 

    Virtually all cases of cervical cancer and its precursor intra-epithelial lesions are a result of infection with one or other of a subset of genital human papillomaviruses (HPVs), suggesting that prevention of HPV infection by prophylactic vaccination would be a highly effective anticancer...

  • Broad-acting HPV vaccines explored to fight cancer. Dorans, Kirsten // Nature Medicine;Apr2009, Vol. 15 Issue 4, p351 

    The article focuses on targeting L2 protein found within the human papillovirus (HPV) for possible development of vaccines that can fight HVP strains that causes cancer. It cites that current marketed HPV vaccines that target protein known as L1 can only neutralize 70% of cervical cancer. Thus,...

  • Vaccines against cervical cancer provoke US controversy. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);4/8/2006, Vol. 332 Issue 7545, p814 

    The article focuses on a new vaccine for cervical cancer which is inciting controversy in the United States from conservative groups concerned that it should not be given to 11 and 12-year-old children, as it may encourage sexual activity. The function of the vaccine, which targets the sexually...

  • HPV vaccine could save millions of lives. Mitrzyk, Beatriz Manzor // Pharmacy Today;Aug2006, Vol. 12 Issue 8, p11 

    The article offers information on the human papillomavirus vaccine (Gardasil) manufactured by Merch & Co. Inc. Gardasil has been found to prevent cervical cancer and genital warts. The U.S. Food and Drug Administration licensed the vaccine for girls and women from between 9 to 26 years old....

  • Find out more about Gardasil.  // Hudson Valley Business Journal;3/5/2007, Vol. 18 Issue 10, p9 

    The article reports on the significance of Gardasil, the current treatment for cervical cancer and the new vaccine, in which the St. Luke's Hospital in Cornwall, New York is offering a free community program to educate more about it. According to sources, it is the only vaccine that may help...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics